Investment Rating - The report rates the industry as "Outperform" [1] Core Insights - The ongoing US-China trade tensions are intensifying the urgency for domestic chip production, particularly in high-performance computing [4][12] - The introduction of the NVIDIA H20 chip has led to increased competition among domestic chip manufacturers, highlighting the need for differentiation in performance and capabilities [14][17] - TSMC reported a significant revenue increase of 41.76% year-on-year, with a net profit growth of 60.3%, indicating strong demand for advanced semiconductor processes [24] Summary by Sections Section 1: Chip Export Restrictions - The US government has imposed export restrictions on NVIDIA's H20 chip to China, which has prompted a shift towards domestic chip development [8][12] - The H20 chip, manufactured using TSMC's 4nm process, features 296 TFLOPS FP8 performance and 148 TFLOPS FP16 performance, but faces competition from domestic alternatives like Huawei's Ascend 910B [14][15] Section 2: Global Industry Dynamics - Intel and MAXHUB launched a new enterprise-level AI PC aimed at enhancing AI model deployment at the edge [20] - NVIDIA plans to produce AI supercomputers entirely in the US, indicating a strategic shift in manufacturing and supply chain management [22][23] - TSMC's first-quarter results exceeded market expectations, with advanced process technologies contributing significantly to revenue [24][25] Section 3: Market Performance - The electronic industry experienced a decline of 0.6% in the past week, ranking 26th out of 31 sectors [4][32] - Notable stock performances included Si Rui Pu (+26.0%) and Shi Hua Technology (+22.7%), while stocks like Kai De Quartz (-17.9%) and Min De Electronics (-10.7%) faced significant declines [4][36][37]

Investment Rating - The report rates the industry as "Outperform" [1] Core Insights - The ongoing U.S.-China trade tensions are intensifying restrictions on high-performance computing chips, particularly affecting the export of NVIDIA's H20 chips to China, which may accelerate the development of domestic alternatives [8][12] - TSMC reported a significant revenue increase of 41.76% year-on-year, with a net profit growth of 60.3%, highlighting the strong performance of advanced process technologies [24][25] - The report emphasizes the urgency for domestic chip manufacturers to innovate and capture market share in the high-performance computing segment due to export restrictions on foreign chips [14][24] Summary by Sections Industry Performance - The electronic industry experienced a decline of 0.6% in the past week, ranking 26th out of 31 sectors, while the Shanghai Composite Index rose by 0.6% [4][32] - The top-performing sub-sectors included analog chip design (+3.1%) and panels (+1.7%) [36] Stock Performance - Notable stock performances included Si Rui Pu (+26.0%) and Shi Hua Technology (+22.7%), while stocks like Kai De Quartz (-17.9%) and Min De Electronics (-10.7%) faced significant declines [4][37] Chip Market Dynamics - The U.S. government has imposed indefinite export licensing requirements for NVIDIA's H20 chips, which has led to a comparative analysis of domestic chips like Huawei's Ascend 910B and Cambricon's MLU370-X8, showcasing their competitive advantages and limitations [14][15][17] - The report highlights the advancements in chip technology from competitors like AMD and Intel, which are also adapting to the changing market landscape [17][19] Global Industry Developments - Intel's collaboration with MAXHUB to launch enterprise-level AI PCs aims to enhance AI model deployment at the edge, reflecting the growing demand for AI capabilities [20][21] - NVIDIA's plans to produce AI supercomputers entirely in the U.S. signify a strategic shift in manufacturing and supply chain management [22][23]

Investment Rating - The report rates the pharmaceutical and biotechnology industry as "Outperforming the Market" [1] Core Insights - The report highlights the strong growth potential in the innovative drug sector, particularly in areas such as ADC (Antibody-Drug Conjugates), dual antibodies, and self-immune therapies, supported by national policies and increasing funding [2][13] - The report emphasizes the importance of capturing opportunities in "hard technology" and "strong demand" within the domestic market amidst uncertainties in the US-China geopolitical landscape [2][12] Summary by Sections 1. Market Review - The pharmaceutical sector experienced a slight decline of 0.36% during the week of April 14-18, underperforming the CSI 300 index, which rose by 0.59% [5][6] - The market is gradually recovering from the impacts of tariff policies, with a shift in focus towards long-term investment opportunities [5][6] 2. Investment Strategy - The report suggests focusing on "hard technology" and "strong demand" sectors, particularly innovative drugs and high-end medical devices, which are expected to benefit from domestic market dynamics [12][13] - The innovative drug sector is identified as the most promising area for growth, with significant support from national policies and funding improvements expected by 2025 [13][14] 3. Company Spotlight: InnoCare Pharma - InnoCare Pharma is recognized as a leading player in the ADC space, with a robust pipeline of 12 self-developed ADC products, six of which are in clinical development [15][18] - The company's core product, DB-1303, is a third-generation HER2 ADC targeting endometrial cancer, with plans to submit for accelerated approval to the FDA in late 2025 [19][20] - InnoCare has established partnerships with major pharmaceutical companies, securing potential milestone payments exceeding $6 billion [18][19] 4. Future Catalysts - The report outlines several upcoming catalysts for InnoCare, including clinical trial advancements for DB-1303 and other ADC products, which are expected to generate significant market interest [28] - The company is also exploring collaborations with BioNTech for combined therapies, indicating a strategic focus on innovative treatment combinations [28][26]

Investment Rating - The report rates the pharmaceutical and biotechnology industry as "Outperforming the Market" [1][36]. Core Insights - The report highlights that the innovative drug sector is the most promising investment opportunity, supported by national policies and expected improvements in payment mechanisms by 2025 [2][13]. - The focus is on "hard technology" and "strong demand" within the domestic market, particularly in innovative drugs and high-end medical devices [2][12]. - The report emphasizes the potential of ADC (Antibody-Drug Conjugates) as a leading area for investment, with companies like Ying'en Biotech recognized for their innovative capabilities and successful partnerships with major pharmaceutical firms [2][15]. Summary by Sections Market Overview - The pharmaceutical sector experienced a slight decline of 0.36% this week, underperforming the CSI 300 index, which rose by 0.59% [5][6]. - The market is recovering from the impacts of tariff policies, with a shift in focus towards long-term investment opportunities [5][12]. Investment Strategy - The report suggests capturing opportunities in "hard technology" and "strong demand" sectors, particularly in innovative drugs and high-end equipment [2][12]. - It notes that the innovative drug sector is recognized for its growth potential, with significant support from the government and increasing recognition from multinational corporations [2][13]. Company Spotlight: Ying'en Biotech - Ying'en Biotech is highlighted as a leading player in the ADC space, with a robust pipeline of 12 self-developed ADC products, six of which are in clinical development [2][15]. - The company has secured over $2 billion in funding through its successful IPO and has established partnerships with major pharmaceutical companies, indicating strong market confidence [2][18]. - The core product, DB-1303, is a third-generation HER2 ADC targeting endometrial cancer, with plans for accelerated approval submission to the FDA in late 2025 [2][19]. Future Catalysts - The report identifies several upcoming catalysts for Ying'en Biotech, including clinical trial advancements for DB-1303 and other ADC products, which are expected to generate significant market interest [2][28]. - The company is also exploring collaborations with BioNTech for combined therapies, enhancing its competitive positioning in the market [2][26].

Investment Rating - The automotive industry is rated as "Outperform" compared to the market [4] Core Insights - The automotive sector experienced a decline of 0.79% this week, underperforming the CSI 300 index which rose by 0.59% [4][12] - Passenger car sales showed a year-on-year increase of 13% in the second week of April, with a total retail of 5.642 million units since the beginning of 2025, reflecting a 6% year-on-year growth [4][12] - The upcoming Shanghai International Auto Show is expected to highlight the acceleration of electric intelligence, with a focus on smart driving technologies [8][10] Summary by Sections Market Overview - The automotive sector's index closed at 6,519.5 points, ranking 28 out of 31 sectors [4][12] - The automotive services sector saw an increase of 1.95%, while passenger vehicles and automotive parts both declined by 0.99% [4][12] Sales Data - In April, the average daily retail of passenger cars was 44,000 units, with leading sales from BYD at 53,400 units [4][12] Regulatory Developments - The Ministry of Industry and Information Technology emphasized the need for automotive companies to conduct comprehensive testing for driving assistance systems, increasing compliance costs and self-research pressures [4][12] Investment Recommendations - For passenger vehicles, the report suggests focusing on companies like Xiaopeng Motors and Xiaomi Group for their advancements in smart driving and intelligent cockpit technologies [4] - In the automotive parts sector, companies such as Kebo Da and Baolong Technology are recommended for their core technology supply chain developments [4] - The report also highlights the growth potential in automotive services, particularly for companies like China Automotive Research [4]

Investment Rating - The automotive industry is rated as "Outperform" compared to the market [4] Core Insights - The automotive sector experienced a decline of 0.79% this week, underperforming the CSI 300 index which rose by 0.59% [4][12] - Passenger car sales showed a year-on-year increase of 13% in the second week of April, with a total retail of 5.642 million units since the beginning of 2025, reflecting a 6% year-on-year growth [4][12] - The upcoming Shanghai International Auto Show is expected to highlight the acceleration of electric intelligence, with a focus on smart driving technologies [8][10] Summary by Sections Market Overview - The automotive sector's index closed at 6,519.5 points, ranking 28 out of 31 sectors [4][12] - The automotive services sector saw an increase of 1.95%, while passenger vehicles and automotive parts both declined by 0.99% [4][12] Sales Data - In April, the average daily retail of passenger cars was 44,000 units, with leading sales from BYD at 53,400 units [4][12] - The overall market for passenger vehicles showed a month-on-month decline but maintained a year-on-year growth trend [4][12] Regulatory Developments - The Ministry of Industry and Information Technology emphasized the need for automotive manufacturers to conduct comprehensive testing for driving assistance systems, increasing compliance costs and self-research pressures [4][12] Investment Recommendations - Focus on companies leading in autonomous vehicle technology and smart cockpit development, such as Xiaopeng Motors and Xiaomi Group [4][5] - In the automotive parts sector, companies like Kobotda and Baolong Technology are recommended due to their core technology supply chain [4][5] - The automotive service sector is expected to expand with the growth of electric intelligent brands, with China Automotive Research being a key player [4][5]

证券研究报告 行业研究 / 行业点评 2025 年 04 月 21 日 行业及产业 机械设备 一年内行业指数与沪深 300 指数对比走势： 资料来源：聚源数据，爱建证券研究所 相关研究 ——爱建智能制造周报（2025/04/14-2025/04/18） 《机器人板块阶段调整，关注成熟制程产能释 放预期——爱建智能制造周报 （2025/04/07-2025/04/11）》2025-04-14 《关税催化内需闭环，"东升西落"下的攻守 请仔细阅读在本报告尾部的重要法律声明 （2025/03/31-2025/04/03）》2025-04-07 《设备为锚，掘金 4 月先进制造景气主线—— 爱建智能制造周报 （2025/03/24-2025/03/28）》2025-03-31 《机械板块成长资金分化，设备厂整合趋势加 速——智能制造周报 （2025/03/17-2025/03/21）》2025-03-24 《人形机器人回调现布局良机，机械设备回暖 共筑新增长极——智能制造周报 （2025/03/10-2025/03/14）》2025-03-16 证券分析师 王凯 S0820524120002 021-32229888 ...

证券研究报告 行业研究 / 行业点评 2025 年 04 月 21 日 行业及产业 机械设备 一年内行业指数与沪深 300 指数对比走势： 资料来源：聚源数据，爱建证券研究所 相关研究 《机器人板块阶段调整，关注成熟制程产能释 放预期——爱建智能制造周报 （2025/04/07-2025/04/11）》2025-04-14 《关税催化内需闭环，"东升西落"下的攻守 （2025/03/31-2025/04/03）》2025-04-07 《设备为锚，掘金 4 月先进制造景气主线—— 爱建智能制造周报 （2025/03/24-2025/03/28）》2025-03-31 《机械板块成长资金分化，设备厂整合趋势加 速——智能制造周报 （2025/03/17-2025/03/21）》2025-03-24 《人形机器人回调现布局良机，机械设备回暖 共筑新增长极——智能制造周报 （2025/03/10-2025/03/14）》2025-03-16 证券分析师 王凯 S0820524120002 021-32229888-25522 wangkai526@ajzq.com ——爱建智能制造周报（2025/04/14-2025 ...

证券研究报告 行业研究 / 行业点评 2025 年 04 月 14 日 行业及产业 机械设备 一年内行业指数与沪深 300 指数对比走势： 资料来源：聚源数据，爱建证券研究所 相关研究 《关税催化内需闭环，"东升西落"下的攻守 之道——爱建智能制造周报 （2025/03/31-2025/04/03）》2025-04-07 《设备为锚，掘金 4 月先进制造景气主线—— 爱建智能制造周报 （2025/03/24-2025/03/28）》2025-03-31 《机械板块成长资金分化，设备厂整合趋势加 速——智能制造周报 （2025/03/17-2025/03/21）》2025-03-24 《人形机器人回调现布局良机，机械设备回暖 共筑新增长极——智能制造周报 （2025/03/10-2025/03/14）》2025-03-16 《C 端机器人市场有望依托软件优化产能爬坡 ——智能制造周报 （2025/03/03-2025/03/07）》2025-03-11 王凯 S0820524120002 021-32229888-25522 wangkai526@ajzq.com ——爱建智能制造周报（2025/04/07-2 ...

证券研究报告 行业研究 / 行业点评 2025 年 04 月 14 日 行业及产业 机械设备 一年内行业指数与沪深 300 指数对比走势： 资料来源：聚源数据，爱建证券研究所 相关研究 《关税催化内需闭环，"东升西落"下的攻守 之道——爱建智能制造周报 （2025/03/31-2025/04/03）》2025-04-07 《设备为锚，掘金 4 月先进制造景气主线—— 爱建智能制造周报 （2025/03/24-2025/03/28）》2025-03-31 《机械板块成长资金分化，设备厂整合趋势加 速——智能制造周报 （2025/03/17-2025/03/21）》2025-03-24 《人形机器人回调现布局良机，机械设备回暖 共筑新增长极——智能制造周报 （2025/03/10-2025/03/14）》2025-03-16 《C 端机器人市场有望依托软件优化产能爬坡 ——智能制造周报 （2025/03/03-2025/03/07）》2025-03-11 王凯 S0820524120002 021-32229888-25522 wangkai526@ajzq.com ——爱建智能制造周报（2025/04/07-2 ...